An interventional study of 2% Melatonin gel and Placebo Gel in Periodontal Diseases, sponsored by Alexandria University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Alexandria University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Periodontal Diseases with a site in Egypt — 9 open to participants now, 13 under way, none of them phase 3. Periodontal Diseases · Egypt.
Among the 66 studies in Periodontal Diseases with a site in Egypt, this one is the 38th largest by planned enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2026, is one of 29 with no phase, reaches primary completion later than 12 of the 12 other live ones, and was the 64th registered.
867 studies on the registry are indexed under Periodontal Diseases; 189 are open to participants now.
Browse Periodontal Diseases studies →9 of the 66 studies in Periodontal Diseases with a site in Egypt are open now. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 20–40 · Healthy volunteers
Al-Azhar University · Sites in Egypt
Ages 30–50
British University In Egypt · Sites in Egypt
Ages 19+
Ain Shams University · Sites in Egypt
Ages 18–60 · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 20–50 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 101 Periodontal Diseases studies recruiting now, 47 (47%) set no upper age limit and 42 (42%) stop at 75 or younger; 5 take children under 18; 58 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 6 · Phase 4 2
First in 2009; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 23 is below the median of 45 across 557 interventional studies indexed under Periodontal Diseases.
Median enrollment 30 across the 47 interventional studies, 120 across the 19 observational. Of the 43 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 66 has an industry lead sponsor. The 10 most frequent:
Alexandria University is the lead sponsor of 606 studies on the registry; 141 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Alexandria University has 2 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Periodontal Diseases with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07731113Cairo UniversityEvaluation of Hyaluronic Acid and Chlorhexidine Gel as an Adjunct to Minimally Invasive Non-surgical Therapy in the Treatment of Stage III and IV Periodontitis | 2026-12-10 |
| NCT07813936Alexandria UniversityLocally Delivered Melatonin Gel in Management of Stage II Grade B Periodontitis | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies in Periodontal Diseases with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues, driven by an imbalance between bacterial pathogens and the host immune response. This inflammatory process leads to the excessive production of reactive oxygen species (ROS), causing oxidative stress and tissue damage. Melatonin is a potent antioxidant and immunomodulator that scavenges free radicals and reduces inflammation. Previous research indicates that salivary and gingival crevicular fluid (GCF) melatonin levels are significantly reduced in patients with periodontitis compared to healthy individuals, suggesting its potential utility as a biomarker for periodontal health.
Aim: The aim of this study is to evaluate the efficacy of 2% melatonin gel administered locally into periodontal pockets as an adjunct to subgingival instrumentation in patients with Stage II Grade B periodontitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: 2% Melatonin gel
Other: Placebo Gel
All qualifying periodontal pockets on the randomly assigned test side will receive Non-Surgical Periodontal Therapy (NSPT) followed immediately by the subgingival application of 2% Melatonin gel.
All qualifying periodontal pockets on the contralateral side will receive Non-Surgical Periodontal Therapy (NSPT) followed immediately by the subgingival application of the Placebo gel.
Change in clinical attachment loss
Measurements will be recorded using a graduated William's periodontal probe
Time frame: Baseline and 8 weeks
Change in Probing Pocket Depth
Measurements will be recorded using a graduated William's periodontal probe
Time frame: Baseline and 8 weeks
Change in Bleeding on probing
Measurements will be recorded using a graduated William's periodontal probe
Time frame: Baseline and 8 weeks
Change in Melatonin levels in Gingival Crevicular Fluid
The collected GCF samples will be analyzed using a commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kit specific for human melatonin
Time frame: Baseline and 8 weeks
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 312 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 12 months is close to that.
Counting every sponsor, half of 331 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.